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ABSTRACT 
An overactive bladder (OAB) is a syndrome which causes an impulsive desire to pass the urine. This desire or urge may become difficult to control 
and eventually may lead to unintentional passage of urine. The marked increase in a number of patients who suffered with OAB feels very awkward 
and tries to isolate from societal-life. Such increase in a number of patients has drawn an attention of scientists to research on this area. The proper 
diagnosis and management of OAB can help the patient to get early relief and cure the symptoms. Looking at the rate of prevalence of OAB in 
patients, it is essential to understand the pathophysiology, available treatment and recent updates to direct the researchers for further 
investigation. This review article focuses on comprehensive information of normal bladder physiology, neural control, regulation of micturition, 
pathophysiology, and prevalence of overactive bladder. This article gives an information regarding diagnosis, different approaches for treatments 
and future perspective of OAB syndrome. 
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Since the last two decades, people suffering from OAB syndrome/ 
symptom has increased enormously worldwide and is anticipated 
that it will cross 546 million populations by 2018. The annual 
worldwide healthcare cost for OAB is enhanced from €1.4 trillion to 
€ 3.2 trillion by 2018. Though the percentage of both male and 
female patients is most similar it is slightly more in women 
population [1]. In the initial phase of OAB syndrome, individual may 
not understand the indication of urine urgency which may occure 
due to the large volume of liquid intake, any physical exertion, 
stress-induced or any other defect occurred in the body functioning. 
At the initial stage, it is very difficult for both patient and physician 
to identify the symptoms of OAB [2]. Thus, making a note on the 
diary with date and time with respect to fluid intake, voiding and 
urine leakage will help to identify the symptoms of OAB. For 
physicians, it is necessary to evaluate the basic and clinical impact 
and get a detailed patient history to diagnose OAB. In clinical 
practice, the syndrome of OAB can be defined as a condition which is 
characterized by urinary urgency, with or without urge 
incontinence, usually with urinary frequency and nocturia [3]. 
Debbie Kinsey and colleagues revealed that the patients suffered 
from OAB are psychologically very disturbed and lived a lower 
quality of life than normal people [4]. This review article provides an 
insight of the neural control, bladder physiology, regulation of 
micturition in a normal individual and also disrupt the mechanism of 
micturition in OAB patients along with the risk factors, prevalence, 
assessment, management and future perspective of OAB. For this 
review article, an extensive literature survey was carried out on 
search engines including Pubmed, Science Direct, Google scholar by 
referring keywords as subsections mentioned in this article and 
collect the information available tentatively from year 1980.  
Neural control, bladder physiology and regulation of micturition 
The continuous efforts are taken in order to understand the complex 
and highly distributed functioning of neural control of urinary 
bladder and urethra which results in the process of micturition. The 
role of neural ascendancy on the bladder and urethra are to facilitate 
urine discharge when the mechanical, emotional and social 
circumstances are appropriate. The synchronized activities of 
urinary bladder for urine collection and discharge are managed by 
the central and peripheral nervous systems which are mediated 
through multiple neurotransmitter systems [5]. The various parts of 
the body involved in this coordination are the brain, smooth and 
striated muscles of the urinary bladder, bladder neck, urethra and 
urethral sphincter [6, 7]. In brief, during the time of storage of urine 
in the bladder, the detrusor muscle undergoes destress or unbend 
while the external urethral sphincter gets contracted and the 
information related to bladder filling is continuously sent to the 
central nervous system (CNS). Inversely, during micturition, the 
bladder contracts and the external urethral sphincter come into 
relaxation mode, and results in to the discharge of urine [8]. The 
detailed mechanism of neural control and regulation of micturition 
are shown in fig. 1. At the top of spinal cord, there is a main control 
center in the Pons (the part of the brain-stem that links medulla 
oblongata and the thalamus) where it unswervingly stimulates the 
bladder neurons. This center restrains the urethral sphincter, which 
synchronizes bladder contraction and sphincter relaxation and 
eventually the bladder gets void. The nervous system at several 
levels regulates the bladder and urethral sphincters, particularly the 
sacral segments and the Pons. The lower urinary tract (LUT) is 
innervated by hypogastric, pudendal and pelvic nerves of 
sympathetic, somatic and parasympathetic nervous systems 
respectively. These nerves have both afferent as well as efferent 
axons. The nervous systems involved in efferent and afferent actions 
lead to urine accumulation and further urine release from the 
bladder. 
In the first stage, the sympathetic innervation is initiated between 
detrusor and the urethral sphincter. The connection between 
brain and LUT is at the T10–L2 level of the spinal cord via 
sympathetic outflow. This innervation provides a noradrenergic 
inhibitory action at bladder body and excitatory effect at bladder 
base and proximal urethral sphincter inputs via release of 
noradrenaline on β3-adrenergic receptors and α1-adrenergic 
receptors respectively. This results in activation of hypogastric 
nerve, which persuades the loss of tension of bladder body by β 3-
adrenergic receptors and narrow bladder opening and urethra 
through α1-adrenergic receptors. This sympathetic activation 
contributes for urine storage in the bladder and maintains storage 
for prolonged time [5, 8-12]. β-adrenergic receptors are also found 
in urothelium [13, 14]. During the urine storage phase, the volume 
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of apical umbrella cells enhances the stretching of the bladder 
muscle. At the same time some mediators release and excite the 
sensory fibers [15]. In the second stage, the striated urethral 
sphincter (SUS) is innervated by somatic motor neurons which are 
located in Onuf's nucleus [6, 16]. Pudendal nerves appear from S2-
S4 levels that excite the distal SUS. Activation of sacral somatic 
nervous system results in tightening of SUS. In the third stage, 
pelvic nerves which are the part of the parasympathetic nervous 
system are responsible for release of excitatory transmitter 
acetylcholine binds to M3 muscarinic receptor which provokes the 
contraction of bladder and relaxation of urethra. This contributes 
to urinary bladder emptying [9, 17]. In additional mechanism, 
adenosine triphosphate (ATP) binds to P2X 1
OAB 
 purinergic receptors 
on detrusor muscle and leads to contraction [9, 18]. The inhibition 
of the urethral smooth muscles may also happen due to nitric 
oxide, which is released through parasympathetic nerves [19]. As 
reported earlier sympathetic, somatic and parasympathetic 
nervous systems exert an action by both efferent and afferent 
axons. Afferent axon transmits the sensation from LUT to the 
spinal cord. Sensations of bladder fullness due to increase in 
volume and wall tension, are transmitted to the spinal cord by the 
hypogastric and pelvic nerves [6, 20], while the pudendal and 
hypogastric nerves, specifically the sensory input are passed 
through the bladder neck and urethra. Moreover, the pelvic 
afferent nerve consists of two fibers myelinated Aδ axons and 
unmyelinated C fibers. The myelinated Aδ axons are sensitive to 
unreceptive expansion and dynamic tightening [20] and hence 
transmit the information of the bladder filling whereas the 
unmyelinated C fibers react actively to noxious stimuli for cooling 
[21] or chemical irritation [22]. In a physiological condition such 
as spinal cord injury (SCI), these unmyelinated C fibers are not 
sensitive to bladder filling. In periaqueductal grey matter (PAG), 
middle pons and frontal lobe area, it was observed that the 
improvement in the brain activity relates to the bladder volume 
[23]. The coordination of efferent and afferent actions revealed 
that after filling the urinary bladder, the afferent signals from the 
receptors in the wall of the bladder and the urothelium are 
promulgated towards higher point of PAG [23, 24] through the 
sacral spinal cord [25]. A switching action is activated when these 
afferent indications attain an adequately high intensity and 
subsequently increase the efferent signals which move down via 
the spinal cord and stimulate the sacral sections. This leads to the 
detrusor contraction and also endorses urethral sphincter 
relaxation which ultimately initiates micturition. Afferent neurons 
will carry on conflagration and empty the bladder till it gets 
completely vacant [5]. 
The normal function of LUT is characterized by the capacity to stay 
incontinence during urine accumulation and emptying bladder as 
per the individual convenience after receiving the sensation of 
bladder fullness. Such function is controlled by neural and 
micturition regulation mechanism. Interruption in these organized 
functions lead to irregular urine accumulation and discharge. The 
disturbances in the afferent nerve regulation of bladder function will 
affect the urine storage and emptying system coordination [26]. The 
indications of OAB are urgency, frequency, nocturia and urge 
urinary incontinence [2, 3]. There are three different causes of OAB 
such as neurogenic, non-neurogenic and idiopathic. In neurogenic 
etiology, most of CNS conditions such as stroke, Parkinson's disease, 
traumatic brain injury, multiple sclerosis (MS), SCI, etc. have been 
associated. In non-neurogenic etiology, bladder outlet obstruction, 
bladder infection, chronic cystitis, bladder cancer, bladder stone, etc. 
are associated with OAB with respect to age [3]. Smooth muscles of 
urinary bladder are known as detrusor muscles and comprised of 
body or dome and base. β-adrenergic and cholinergic receptors are 
predominantly present at the dome, while α-adrenergic receptors 
are located at the base and the proximal urethra [17, 27]. The 
parasympathetic motoneurons are responsible for release of 
excitatory neurotransmitter acetylcholine, and interact with the 
muscarinic receptors. This results to tightening of bladder muscle 
and relax urethra which leads to the bladder emptying [9]. Amongst 
the 5 muscarinic receptors, subtypes M2 and M3 are the principle 
receptors sited on the bladder, whereas M3 receptors are overriding 
for the tightening of the detrusor muscle [17, 28]. During bladder 
enlargement there is an overstated effect of released acetylcholine 
from the urothelium. Subsequently, response to CNS generates the 
feeling of urgency, premature triggering and also promotes the 
symptoms of OAB [29]. It is also observed that a component in 
muscle or tissue rather than the nerve impulses feel the sensation 
for involuntary rise in the bladder pressure [30]. In the OAB 
syndrome, urinary bladder won’t be full but detrusor overactivity 
and external urethral sphincter will promote the release of urine by 
creating a sensation of urgency [31, 33]. The detailed mechanism is 
illustrated in fig. 1. 
 
 
Fig. 1: Mechanism of neural control on contraction and relaxation of smooth muscle 
 
Factors responsible for risk of OAB 
Problems associated with urinary tract infections may lead to 
impermanent bladder symptoms, which are recoverable. 
Progressive age is a prominent factor which is more likely to 
contribute in OAB symptoms. Other reasons for OAB are 
neurological changes; the drag of gravity or weight may cause pelvic 
base organs to prolapse and susceptible to urinary tract infection 
because of the weaker immune system [34-36]. In women, a 
significant drop in estrogen level observed after menopause, which 
results in thinner and drier tissues of bladder, urethra, and pelvic 
muscle atrophy may be the cause that leads to urgency and 
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frequency of urination [37]. Some conditions like pregnancy and 
childbirth, disease of the nervous system, bladder cancer, pelvic 
surgery, enlargement of the prostate, urinary tract infection, 
overweight, medications like diuretics, sedatives, antidepressants, 
certain occupations like teaching, nursing, police officers, truck/bus 
driving, etc. may cause the risk of OAB. 
Prevalence of OAB 
Progressive age is a primary cause for the increase in the prevalence 
of OAB [36, 38, 39]. As per Milsom, OAB symptoms are more 
prevalent in European countries like France, Germany, Italy, Spain, 
Sweden and UK using a random and stratified approach [36]. In this 
study, the general population of men and women aged over and 
equal to 40 y were selected and younger women showed more OAB 
signs than men whereas the reverse condition was observed in the 
aged population. There was no significant difference in the overall 
prevalence reported in women and men of 16.9% and 16.0% 
respectively when compared the complete population of both. In 
these six European countries total 22 million people will be suffered 
from OAB if extrapolated to the total population of above 40 y of age. 
Irwin conducted a separate study which estimates globally and 
specific area of a base number of people suffered from OAB in 2008 
and predicted for 2018 with the support of their own EPIC study [1]. 
EPIC study was a telephonic survey of 19,165 men and women in 5 
regions [38]. According to this study in 2008, 455 million people 
experienced OAB worldwide and an anticipated increase to 546 
million (20.1%) till 2018. In 2008, the global prevalence was more in 
women (11.6%) than men (9.7%) and also anticipated the similar 
way in 2018 (11.9% vs 10.0%). Asia is the most OAB affected region 
than Europe followed by Africa, North America and South America. 
From 2008 to 2018, there will be an increase in OAB patients in Asia, 
South America and Africa as 22.1%, 22.4% and 31.1% respectively. 
Based on the published economic model [40], it was extrapolated 
that the normal global yearly treatment cost of OAB will be €1.4 
trillion to € 3.2 trillion by 2018 [1]. Other than EPIC and Milsom 
study, some other studies were also conducted by some agencies on 
the prevalence of OAB like National Overactive Bladder Evaluation 
study and The Epidemiology of Lower Urinary Tract symptoms [35]. 
Evaluation and diagnosis  
The patient’s history is of prime importance to elicit the symptoms 
of OAB. The physician considers the LUTS, any medical condition 
related to OAB, dietary habits, bladder storage and emptying 
associated with OAB, ongoing medication, current or past surgical 
problem, any radiation treatment for lower body cancer, physical 
examination (Body mass index, abdomen, genitalia, relevant pelvic 
examination, neurologic, mental status), urine analysis, urodynamic 
testing, post-void residual (PVR) measurement with an ultrasound 
bladder scanner, urine cytology, cystoscopy etc. There must be 
check on the of observable urinary tract disease. In normal healthy 
patients the range of frequency is four to eight voids per 24 h, thus 
additional voids may be significant to assess OAB. The information 
to be received from the patient through questionnaire should 
include number of voids in a day divided as daytime and nighttime, 
amount of urine over 24 h, utmost discharged urine amount, average 
and highest urine amount, and night-time urine amount. An 
evaluation of lack of voluntary control over urination in terms of 
seepage episodes and usage of can also be obtained. The overall 
history, monitoring, test outputs will help to a physician for the 
evaluation of OAB and accordingly set the treatment approaches [2, 
35, 41-44]. 
Treatment for OAB 
Lifestyle intervention, behavioral treatments, bladder training 
After receiving the information from the patient through 
questionnaire and the regular monitoring activities through the 
bladder diary, the physician may initiate the treatment based on the 
intensity and the cause of OAB. The lifestyle intervention includes 
altering fluid intake, smoking termination, avoid bladder irritants 
like organic and carbonated beverages, coffee, body weight 
reduction, adapting bowel role to avoid constipation and spraining 
during bowel movements and sleeping time [35, 41, 42]. In 
behavioral treatment, the patient has to be trained in improving the 
control to restrain or disrupt detrusor tightening. To manage the 
seepage of urine, a deliberated pelvic floor muscle tightening should 
be practiced which makes possible to get better stress within the 
urethra and hinder the detrusor tapering. In the elderly population 
after the physical examination training for two seconds as 
mentioned above with fifteen replication has to be scheduled and 
this should be followed thrice a day. The patient should 
progressively increase this practice by almost one second every 
week, till they attain ten second tightening and relaxations. 
Gradually the patient is trained to uphold the urination in such a 
way that, whenever he/she feels the urgency, rather than running to 
the washroom, individual waits and calms down and squeezes the 
pelvic floor muscles exclusively until the pressure is gone. The 
practice of walking towards the washroom at regular speed should 
be repeated whenever the sense of urgency arises. Trained 
professional shall instruct the patient for at least 3 mo to see the 
benefits of these instructions [41, 42, 44, 45]. In the bladder training 
program after reviewing the bladder diary of a patient, the physician 
has scheduled the longest comfortable interval between voiding the 
bladder in object to reduce its frequency. The patient is trained to 
empty the bladder after awakening, then at a pre-scheduled time of 
the whole day and finally before going to bed. In case if the sense of 
urgency occurs between prefix intervals, the patient is trained to 
tighten the pelvic floor muscles until the schedule voiding time have 
been reached. After 1-2 w, the patient is trained for gradually 
increasing time distance between the urination. During this training 
the patients are encouraged to sit down in urgency, take slow, deep 
breaths and concentrate on breathing instead of bladder sensation 
[42, 46]. For the above mentioned programs, the exercises must be 
completed daily with motivation to patience. If these measures fail 
to control the symptoms, then anticholinergic medications are 
added [33, 38, 43]. 
Anticholinergic or antimuscarinics drug 
As described in the first section of this review, the parasympathetic 
postganglionic nerves, releases neurotransmitter acetylcholine, this 
binds to the muscarinic receptor M3 on the detrusor muscle which 
results to the contraction of the bladder [9, 18]. In OAB patient, 
during the bladder filling, the anticholinergic drugs competitively 
inhibit acetylcholine binding to M3 receptor as shown in fig. 1 and 
avoid instinctive tightening of the bladder. Secondly, anticholinergic 
drugs inhibit potentially urothelial sensory receptors and decrease 
afferent nerve activity, i.e. sensory inputs from the bladder [41, 42, 
47-51]. These drugs enhance the capacity of the bladder at the first 
automatic contraction response [2, 47, 52]. Since the anticholinergic 
drugs act competitively, the immense discharge of acetylcholine 
during urination will curtail the active moiety consequence and 
detrusor muscle squeezes [42]. The selective anticholinergic drugs 
have more affinity for the M3 receptor and therefore may reduce the 
side effects associated with these drugs [35].  
Commonly used anticholinergic drugs are oxybutynin, darifenacin, 
solifenacin, tolterodine, fesoterodine, trospium, flavoxate, 
propantheline, propiverine [1, 32, 35, 41, 42, 53]. Flavoxate [2] and 
propantheline [54, 55] are considered as the antispasmodic drug 
with anticholinergic activity. Flavoxate acts by involving 
intracellular cAMP accumulation and calcium obstructive action. It 
restrains the bladder tightening persuaded by different agonists or 
by electrical stimulation and decrease the occurrence of the bladder 
emptying. It enhances the bladder space capability and decreases 
urination pressure [56]. Propiverine inhibits the calcium invasion 
and modulates calcium of intracellular in urinary bladder smooth 
muscle cells causing musculotropic spasmolysis.  
Due to anticholinergic action it also inhibits the efferent correlation 
of the nervous pelvicus [57]. Constipation and dry mouth are two 
most common adverse effects of the anticholinergics. Amongst the 
aged individuals serious side effects of antimuscarinics are cognitive 
deficits and confusion along with CNS effects such as insomnia, 
dizziness, sedation [2, 35, 41, 42]. After initiation of the therapy, 
careful management is required considering side effects, dose, 
dosage form, and pharmacokinetic-pharmacodynamic of individual 
drug [42]. 
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β3-adrenergic agonist drug 
During the urine storage phase in the bladder, the sympathetic 
nerves release norepinephrine (noradrenaline) which binds to the 
β3-adrenergic receptors on the detrusor muscle. It also provides 
inhibitory action resulted in a relaxation of the bladder [5, 8, 9]. The 
single and only approved drug mirabegron acts as a potent and 
selective β3
This is a strong neurotoxin formed by Clostridium botulinum. It 
works by restraining the calcium intervened discharge of 
acetylcholine at the pre-synaptic neuromuscular intersection in 
peripheral nerve endings and facilitates in impermanent flaccid 
muscle paralysis [71, 72]. This binding of the toxin to the peripheral 
and central nerve ending is well discriminated [73]. The molecule 
gets absorbed by attaching to the neuronal cell membrane with the 
heavy chain [72, 74]. Then a disulfide reaction disconnects the heavy 
and the light chain. The free light chain attached to the acetylcholine 
vesicles performs as a zinc-dependent endopeptidase which divides 
in numerous proteins required for the combination of neuro-
transmitter vesicles with the cell shell, and avoids acetylcholine 
exocytosis and confectioning the neuromuscular end-plate [72, 75]. 
The reconstituted solution is administered in the bladder through 
injection via flexible or rigid cystoscope which is kept away from 
trigone and base. A total of 15 to 20 injections may be required 
during management of the OAB. Summary of the Product 
Characteristics of BOTOX® 100 Units was describing the spot of 
injections in the urinary bladder [71, 76]. Possible side effects of 
Botulinum toxin A may include generalized diplopia, blurred vision, 
dysphasia and weakness. 
Neuromodulator implants 
Sacral neuromodulation is an operative treatment for individuals 
with refractory OAB. Tanagho and Schmidt are the pioneers of this 
surgery in which an electrode is to be implanted in the S3-S4 sacral 
foramen to create persistent electric sacral nerves activation and 
reinstate normality for emptying behavior [77]. Basically, this 
surgery is divided into two stages, in the first phase the efficacy of 
implantation has been demonstrated and then second phase follows 
permanent implantation. A tinned quadripolar lead is inserted 
through the skin into the S3 foramen using bony landmarks and 
fluoroscopic guidance. The nerve core is stimulated electrically to 
judge the position. To evaluate the correct placement of quadripolar 
lead there are some responses to be observed in the toes, rectum, 
labia, penis and vagina. An external pulsate maker is coupled to the 
quadripolar lead after positioning in S3 foramen which has the 
ability to alter the activation force, frequency and pulse width. Fifty 
percent or more cure in OAB condition is the criteria for device or it 
should be removed if no improvement is observed [78, 79]. Although 
the considerable use of sacral neuromodulator is observed in past 
decades, the exact mechanism remains feebly illuminated. Leng and 
Chancellor have stated that the automatic urination is caused due to 
the activation of the unmyelinated C fibers and alpha-myelinated 
afferent fibers in pelvic and pudendal nerve roots [80]. Electric 
stimulations produced by sacral neuromodulator stimulate the 
pacemaker of the bladder and are capable of restraining the neural 
reflexes [81]. According to the additional mechanism, the sacral 
neuromodulator imparts straight hindering efforts to the bladder, 
which repress OAB and develops urinary withholding [82]. There 
are number of complications noted due to the neuromodulator 
implants which need surgical correction involves the relocation of 
the device due to pain. The most commonly observed side effects are 
pain at stimulator site, pain due to misplacement of lead, temporary 
electric shock [83]. It is used in pregnancy, but remains unclear and 
undetermined whether associated with teratogenic effect. Overall, 
this is a complicated treatment and adverse events are dependent 
on the type of complication [79]. 
Augmentation cystoplasty 
An augmentation cystoplasty (AC) is a surgical operation for bladder 
enlargement (increasing the size of the bladder). Bladder 
augmentation was found to be useful, especially with underlying 
neurological disorders such as SCI, MS and myelodysplasia. 
Detubularised patch of the ileum is the most frequently used bowel 
segments for AC. While ileum is not suitable for augmentation, 
sigmoid colon is the most common alternative. Augmentation 
caecocystoplasty (the caecum) and augmentation gastrocystoplasty 
(the stomach) can also be used in this surgical procedure [84]. The 
results of both autoaugmentation and ureterocystoplasty are either 
poor [85] or revision of surgery is required [86]. The AC involves 
there is a high risk of complications such as prolonged postoperative 
ileus, transient urinary fistula, wound infection, bleeding which 
requires reoperation, metabolic complications, acid-base and 
electrolyte disturbances, haematuria-dysuria syndrome in 
gastrocystoplasty, peptic ulceration and/or perforation of the 
bladder, urinary stone formation after augmentation, potential 
increased risk of malignancy, bowel disturbance and urologic 
surgery after AC [84]. 
New drug delivery system (NDDS) for urinary bladder diseases 
-adrenoceptor agonist as demonstrated by in vitro 
laboratory experiments. In mammalian species, it relaxes the 
smooth muscle of the bladder through the increased cAMP 
concentrations in the tissue. In OAB rat models, mirabegron 
enhances the average emptiness volume per urination, reduces the 
frequency of non-voiding tightening and increases the bladder 
capacity without disturbing discharge stress and enduring urine 
volume. Mirabegron illustrates decreased annulled incidence. Hence, 
mirabegron can be used in patients who stop the previous 
anticholinergic therapy [58-61]. Some of the common side effects of 
mirabegron are tachycardia, urinary tract infections, nausea, 
constipation, headache, diarrhea, dizziness and uncommon or 
irregular heartbeat, increased blood pressure, angioedema [62, 63]. 
Other agents 
Desmopressin acetate 
It is a synthetic analogue of antidiuretic hormone (ADH) vasopressin 
which is formed by the hypothalamus and preserved in the posterior 
pituitary gland [2, 64]. The primary role of ADH is to control 
extracellular fluid volume in the body. Desmopressin acts on the 
kidneys by reducing the amount of urine produced at night and also 
responsible for re-absorption of water by kidney [65, 66]. 
Desmopressin acts by imitating the ADH role. Due to hyponatremia, 
the nasal dosage form is no more indicated for primary enuresis [2, 
65, 67]. As such desmopressin is a safe medicine with less side 
effects such as a headache, stomach ache and occasional emotional 
disturbance [68]. 
Tricyclic antidepressants 
Imipramine and amitriptyline have been used for OAB treatment 
due to their multiple actions as an anticholinergic as well as an 
alpha-agonist action [2, 69, 70]. Their antimuscarinic activity is 
feebler than the others of the same category. There is a limitation of 
imipramine use amongst the old aged patients for OAB syndrome 
[70]. However, it has been mentioned that due to the central effect of 
the automatic emptiness, imipramine has been suggested to 
combine with the urge–stress incontinence especially in older 
women [34]. The side effects observed are vast including dry mouth, 
constipation, stomach pain, nausea, cardiac arrhythmias, urinary 
retention and drowsiness [35]. 
Invasive therapies 
When patients are not responding to the medications and therapies, 
the physician may offer a highly specialized and expensive therapy 
such as Bolulinum toxin A. In most of the cases, tolerability can be 
limited due to significant side effects, although in some cases it 
shows a significant clinical success. Following are the invasive 
therapies used to treat severe OAB condition. 
Botulinum toxin A  
The conventional drug delivery system may lead to the fast 
absorption from gastrointestinal tract resulting to minimum efficacy 
with side effects of the drug. The long-acting targeted drug delivery 
system is used for treatment or management of OAB syndrome with 
fewer side-effects and better patient compliance. Table 1 illustrates 
the NDDS available or under development for the drug delivery to 
treat OAB syndrome. 
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Table 1: Different NDDS dosage forms with their applications 
S. No. Drug name NDDS Application Remark References 
1 Botulinum neurotoxin 
serotype A (BoNT-A) 
Liposome OAB Modulate afferent neurotransmission 
by penetrating in urothelium 
87 
2 Oxybutynin Iontophoresis OAB Enhancement of transdermal drug 
transport 
88 
3. Tacrolimus Liposome Prophylaxis of transplant 
rejection 
Systemic side effects are minimum 
since locally acting 
89 
4. Epirubicin Polymeric 
nanoparticles 
In range of neoplastic conditions Improved penetration in to bladder 
wall 
90 
5. Doxorubicin Magnetic 
nanoparticles 
In cancer treatment Diffusion occurs in the bladder wall 90 
6. Nanocrystal Nanocrystalline 
silver 
Decrease bladder cancer necrosis 
factor-α, urine histamine and 
mastcyte activaion with no lethal 
effect. 
Introduced intravesically 90 
7. 5-aminosalicylic acid Mucoadhesive 
nanoparticles 
A derivative of Chitosan i.e. N-
sulfonato-N, O-carboxymethyl 




5-aminosalicylic acid Dendrimers Decrease the loss of color of a 
fluorochrome, protoporphyrin
Core-shell macromolecules having a 
high degree of controlled drug-release 
pattern 
 IX 




9. Tolterodine Transdermal 
hydrogel 
OAB Prolonged pharmacological response 







The plethora of research illuminates in this review provides 
information of OAB and its different therapies like behavioural 
modification, drug therapy and the combination of both. For the 
evaluation and initiation of these therapies, a urologist should 
collect the history of the patient, information about life-style, 
urination of patient and perform a physical examination, different 
tests like urine analysis. If the symptoms are not managed by these 
treatments, then invasive therapies like botulinum toxin A injection, 
neuromodulator implants, augmentation cystoplasty may be 
exploited by a physician with complete control and balancing the 
efficacy and complications or side effects of invasive therapies. In 
future, researchers have to explore the drug therapies with limited 
side effects and high beneficial for the patients over an available 
class of drugs. Antimuscarinics are mostly used as first-line therapy, 
but showed many side effects due to less receptor selectivity. Hence, 
it is necessary to investigate more selective antimuscarinic agents. 
Invasive therapies are slowly getting popular in OAB patients 
despite of more complications than efficacy percentage. 
Investigators are needed to pay an attention for decreasing the 
complications and side effects of these therapies and simultaneously 
improving the relief ratio. Moreover, educational resources should 
be provided to the people for creating awareness, especially in 
women population to let them understand the issue and accordingly 
the healthcare services can be provided. 
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